Arraystar

Executive Summary

Arraystar, founded in 2008 and headquartered in Rockville, MD, is a privately held biotechnology company specializing in innovative tools and sample-to-data services for RNA research, with a particular focus on non-coding RNAs (ncRNAs) including circular RNAs, tRNA fragments, and RNA modifications. The company serves the life science discovery market in genetics and genomics, providing critical analytical solutions that enable researchers to decode the complex roles of ncRNAs in health and disease. As the field of RNA therapeutics and diagnostics rapidly expands, Arraystar is well-positioned to capitalize on the growing demand for specialized RNA analysis tools. Despite a lack of recent public funding or product launches, the company has established a niche in the increasingly important ncRNA space, supporting both academic and biopharmaceutical clients. Its sustained operations since 2008 demonstrate resilience and a track record of serving a specialized market. However, as a private company with limited publicly available financial or pipeline data, its growth trajectory is less transparent than publicly traded peers. The conviction score reflects a moderate level of confidence based on its established market presence and the tailwinds from RNA research funding, tempered by the absence of recent disruptive catalysts or disclosed commercial progress.

Upcoming Catalysts (preview)

• Q4 2026Launch of a novel high-throughput circular RNA detection platform60% success
• Q1 2027Strategic partnership with a top-20 pharmaceutical company for RNA modification analysis40% success
• Q2 2027Series B funding round to expand production capacity and sales team50% success